AI Consensus Investment Thesis
Doximity (DOCS) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$29
+10.6%5-Year
NEUTRAL$47
+79.5%Latest flagship insight
Healthcare Professional Network Monopolist Exploits Market Mispricing Through Aggressive Buybacks
High consensus confirms the platform's entrenched monopoly across verified United States physicians, generating 46% free cash flow margins and an 8% net buyback yield. Sharp divergence surrounds whether rising compute costs and zero-priced competitors permanently cap terminal growth or whether clinical artificial intelligence unlocks premium enterprise software monetization.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Machiavelli (Insider), Universal Investor (Polymath), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Elon Musk (Visionary), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Doximity at the forecast anchor (2026-09-18): $17,947 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 26.28 | +0.65% | +0.65% | Early fiscal 2027 second-quarter results confirm revenue guidance stabilization, but elevated artificial intelligence infrastructure costs and high stock-based compensation cap margin recovery. Programmatic share repurchases absorb selling pressure, establishing an initial valuation floor. |
| Q1 2027 | 27.04 | +2.89% | +3.56% | Calendar 2027 pharmaceutical marketing commitments demonstrate steady baseline renewals. Cash flow generation remains strong, while persistent share retirements slightly increase per-share figures, overcoming broader technology multiple compression driven by restrictive interest rates. |
| Q2 2027 | 28.03 | +3.67% | +7.36% | Full-year fiscal 2027 results reveal that research spending growth is beginning to crest. Conservative initial fiscal 2028 guidance tempers enthusiasm, though free cash flow generation exceeding $300 million reassures institutional allocators. |
| Q3 2027 | 28.88 | +3.03% | +10.61% | Initial commercialization data from point-of-care clinical search sponsorships emerges. While inference overhead keeps gross margins near 85%, modest operating leverage and ongoing float retirement support a steady, measured price advance. |
| Q4 2027 | 30.25 | +4.74% | +15.86% | Pharmaceutical commercial clients increase second-half digital allocations to defend branded drugs facing patent expiries. Health systems expand enterprise workflow software trials, diversifying cash flows and improving forward visibility. |
| Q1 2028 | 31.36 | +3.66% | +20.10% | Fiscal 2028 concluding numbers demonstrate revenue growth stabilizing near high single digits. Cumulative share repurchases reduce diluted share counts below 180 million, mechanically compounding earnings per share across institutional holdings. |
| Q2 2028 | 32.23 | +2.78% | +23.43% | Fiscal 2029 guidance reflects steady mid-single-digit expansion. The resolution of legacy securities litigation risks reduces governance discounts, allowing pristine debt-free balance sheet cash reserves to receive full valuation credit. |
| Q3 2028 | 33.28 | +3.25% | +27.45% | Macroeconomic interest rate stabilization supports mid-cap healthcare software multiples. Verified prescriber active engagement metrics remain resilient above 800,000 clinicians, effectively defending core digital advertising inventory pricing against venture-funded competitors. |
| Q4 2028 | 34.53 | +3.78% | +32.26% | Year-end pharmaceutical budget deployments flow heavily into verified physician digital channels as consumer television ad restrictions take effect. Record quarterly cash generation funds continuous open-market share cancellations. |
| Q1 2029 | 35.63 | +3.17% | +36.46% | Annual life-sciences contract renewals show steady net retention rates. Margins stabilize as engineering productivity normalizes and unit compute costs decline, delivering a solid quarterly operating earnings expansion. |
| Q2 2029 | 36.97 | +3.77% | +41.60% | Fiscal 2029 closes with annual revenue surpassing $800 million. Operating margins recover toward 36%, proving that earlier technology outlays expanded platform utility rather than causing structural operational decay. |
| Q3 2029 | 37.89 | +2.47% | +45.10% | Seasonal late-summer trading brings modest valuation consolidation. Underlying cash flows compound steadily as enterprise hospital contracts for scheduling and credentialing expand across regional healthcare networks. |
| Q4 2029 | 39.20 | +3.46% | +50.12% | Pharmaceutical marketing deployments accelerate across oncology and immunology pipelines. High-margin digital detailing modules convert incremental top-line gains directly into discretionary cash, sustaining disciplined capital return execution. |
| Q1 2030 | 40.14 | +2.42% | +53.75% | Enterprise software subscriptions reach approximately 20% of blended corporate sales, reducing dependence on cyclical advertising. Steady float retirement continues providing mechanical EPS accretion ahead of baseline sales growth. |
| Q2 2030 | 41.15 | +2.50% | +57.60% | Fiscal 2030 full-year results reflect diluted shares dropping toward 160 million. Institutional investors reclassify the platform as an enduring medical communications utility, establishing an unshakeable premium valuation baseline. |
| Q3 2030 | 42.23 | +2.62% | +61.72% | Quiet summer operations highlight durable cash-flow generation. Despite presence of free clinical point tools across the industry, Doximity's encrypted messaging, dialer ubiquity, and verified network defend customer retention. |
| Q4 2030 | 43.41 | +2.80% | +66.25% | Strong fourth-quarter promotional bookings and enterprise hospital software renewals deliver clean earnings execution. Unencumbered liquidity shields operations entirely from broader credit volatility and corporate borrowing pressures. |
| Q1 2031 | 44.43 | +2.36% | +70.18% | Fiscal 2031 concludes with annual free cash flow crossing $420 million. Consistent capital allocation and disciplined management cement high returns on invested capital across shifting healthcare regulatory environments. |
| Q2 2031 | 45.84 | +3.16% | +75.55% | Mature software economics generate predictable, high-margin cash distributions. Management signals ongoing commitment to share repurchases alongside potential regular dividend initiation, broadening institutional shareholder demand. |
| Q3 2031 | 46.86 | +2.23% | +79.47% | The five-year forecast horizon closes with equity compounding driven by ownership concentration, asset-light cash conversion, and an entrenched professional monopoly operating at durable mid-single-digit secular expansion. |
The base-case investment thesis identifies an asset-light medical workflow monopoly navigating an intensive technological reinvestment cycle. While headline revenue growth has decelerated to mid-single digits amid biopharma procurement caution, core platform engagement remains unmatched, capturing over 80% of verified domestic physicians. Trailing free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry of 46% to 49% generates approximately $300 million annually, supported by zero gross funded debt. Management is aggressively utilizing this liquidity to retire roughly 8% of equity annually, mechanically compounding per-share intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry. Valuation sensitivity centers on whether artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry research expenditures represent temporary growth investments or permanent defensive costs required to fend off native electronic health record competition. The primary counterargument warns that venture-subsidized clinical tools and direct-to-prescriber ad scrutiny could permanently cap net revenue retentionnet revenue retentionRecurring revenue from an existing customer cohort after expansion, contraction, and churn, divided by that cohort's starting recurring revenue.View full glossary entry below 110%, stranding the equity as a mature digital media broker.
Key insights
- Equity compensation running near 20% of revenue partially offsets gross buybacks, meaning true per-share economic accretion compounds near 4-6% net annually.
- Structural gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry from 89% toward 85% reflects permanent variable inference costs rather than transitory operational overhead.
- Federal crackdowns on consumer pharmaceutical advertising will systematically redirect commercial life-sciences budgets toward compliant, audited professional physician channels.
Doximity connects more than 80% of American doctors, creating an essential digital network that drug companies and hospital systems must use to reach medical professionals. While business growth has slowed to single digits because pharmaceutical marketing budgets are tight and new artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry tools require higher spending, the underlying company remains exceptionally profitable. With zero debt and huge cash flow, management is buying back massive amounts of its own stock, boosting the value of every remaining share.
Key insights
- Strong annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry gives the business complete financial safety without needing any bank loans.
- Buying back 8% of shares each year steadily boosts earnings per share even during modest sales growth.
- Free rival medical apps and rising computer server costs could limit how quickly profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry bounce back.
Deep Dive
Prevailing market consensus treats the business as an ex-growth digital advertising vendor whose pandemic-era expansion has permanently stalled. The crowd anchors heavily on fiscal 2027 revenue guidance slowing to 4% to 7%, GAAP net income contraction, CFOoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry turnover, and securities class-action litigation. Investors assume biopharmaceutical commercial budget cuts and rising AI compute expenses will permanently compress operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry below 30%, viewing the stock as a value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus treats the business as an ex-growth digital advertising vendor whose pandemic-era expansion has permanently stalled. The crowd anchors heavily on fiscal 2027 revenue guidance slowing to 4% to 7%, GAAP net income contraction, CFOoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry turnover, and securities class-action litigation. Investors assume biopharmaceutical commercial budget cuts and rising AI compute expenses will permanently compress operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry below 30%, viewing the stock as a value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially underestimates the asset's cash-generation durability and per-share compounding power, resulting in equity underpricing. Market participants fixate on optical GAAP margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry from deliberate research outlays while completely overlooking a 46% normalized free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry margin and an 8% net buyback yield. Crucially, consensus fails to grasp that aggressive share retirement concentrates platform cash flows, allowing per-share owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry to compound at double-digit rates even during modest top-line revenue expansion.
Repricing Catalyst
What could make the market recognize and close that gap? Consecutive earnings releases throughout fiscal 2027 demonstrating stabilized operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry alongside initial commercial revenue from sponsored clinical search modules will catalyze repricing. The first observable trigger will be sequential net revenue retentionnet revenue retentionRecurring revenue from an existing customer cohort after expansion, contraction, and churn, divided by that cohort's starting recurring revenue.View full glossary entry rebounding above 112% and visible float reductionfloat reductionA decrease in publicly tradable shares, often caused by repurchases, acquisitions, or insider ownership changes.View full glossary entry in quarterly filings by early 2027. This tangible evidence of per-share earnings acceleration will force institutional allocators to abandon the ex-growth thesis and re-rate shares toward cash-flow peer multiples.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
Sentiment firmly reflects fear and stabilization across most analyses, agreeing that oversold technical levels provide downside support. The decisive tension is whether the asset is reversing out of cyclical troughcyclical troughThe low point in a business or market cycle before potential recovery.View full glossary entry pessimism or facing structural multiple de-rating into a slow-growth media valuation.
Macro Regime Fit
Does the current market environment support the thesis? Restrictive monetary policy with benchmark policy rates near 4.00% and 10-year Treasury yields near 5.0% acts as a valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry headwind for software equities. However, a zero-debt capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry, over $680 million in liquid reserves, and negligible physical capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry insulate operations from credit contraction. Rising interest rates provide accretive cash yield, turning macro liquidity tightening into a strategic capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry advantage.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement across analyses centers on whether Doximity is an indispensable medical operating system temporarily depressed by an investment cycle, or a mature digital ad broker suffering terminal growth saturation. The bullish framework assumes elevated R&D spending will quickly normalize, allowing operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry to rebound toward 40% as AI Search monetizes. The bearish framework counters that R&D and compute costs represent permanent defensive capital required to prevent EHR incumbents from obsoleting the platform, while heavy stock-based compensation dilutes buyback benefits. Monitoring quarterly gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry against the 85% threshold and tracking enterprise AI subscription adoption will resolve this debate.
Base-Case Forces
Event Risk ScoreModerate57/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Aggressive share cannibalization via buybacks | Capital Allocation | +28% | +26% | Management deploys exceptional free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry into aggressive share repurchases, retiring $432 million of common equity in fiscal 2026 and maintaining an 8% net buyback yield. With zero funded debt and authorized buyback capacity, continuous floatfloatThe number of shares available for public trading in the market.View full glossary entry contraction mechanically accelerates per-share earnings growth, establishing an unyielding floor under equity valuation across the five-year horizon. |
| Entrenched physician professional network monopoly | Competitive Positioning | +26% | +24% | Verified clinician membership covers over 80% of United States physicians and prescribers, creating an unassailable digital network moat. Life-sciences manufacturers have no viable alternative digital channel capable of delivering targeted, audited clinical detailing at scale. This structural chokepoint defends high gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and secures durable, non-cyclical marketing allocations across multi-year budgeting cycles. |
| Commercial point-of-care AI Search monetization | Innovation And Product | +22% | +25% | Integrating Pathway clinical intelligence into commercial AI Search transforms the platform from a passive medical newsfeed into an active diagnostic query marketplace. Over 800,000 active prescribers executing clinical queries allow pharmaceutical brands to bid directly on commercial prescription intent. This unlocks high-intent search budgets, lifting average revenue per prescriber as monetization matures. |
| Secular pharmaceutical digital detailing migration | Sector And Industry | +18% | +19% | Pharmaceutical commercialization continues shifting away from costly, restricted field sales forces toward precision digital detailing. Simultaneously, federal scrutiny on direct-to-consumer television advertising reallocates promotional dollars into compliant, audited physician channels. This structural reallocation insulates platform demand from broader macroeconomic advertising cuts, driving steady high-single-digit top-line expansion across blockbuster therapy launches. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Pharmaceutical commercial marketing budget retrenchment | Sector And Industry | -18% | -18% | Legislative drug price negotiations, Medicare inflation caps, and patent cliffs force top pharmaceutical clients to scrutinize promotional return on investment. Major pharmaceutical sponsors have delayed upfront campaign commitments, compressing net revenue retentionnet revenue retentionRecurring revenue from an existing customer cohort after expansion, contraction, and churn, divided by that cohort's starting recurring revenue.View full glossary entry from historic peaks toward 107%. This commercial caution stretches sales cycles and caps near-term top-line revenue expansion at single-digit rates. |
| Elevated AI compute and engineering overhead | Operational Efficiency | -15% | -19% | Operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry compressed from 39.9% in fiscal 2025 to 33.3% in fiscal 2026, driven by research spending surging over 40% to $131 million. Supporting clinical search, ambient scribing, and specialized reasoning models requires ongoing cloud inference and engineering talent. These recurring variable delivery costs dilute operational leverage, preventing near-term GAAP profits from matching sales expansion. |
| Competitive encroachment by free clinical tools | Competitive Positioning | -14% | -12% | Venture-funded clinical AI tools and incumbent electronic health record systems like Epic and Cerner are deploying free ambient documentation and medical search directly into clinician workflows. Multihoming among physicians threatens session dwell time and caps Doximity's pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry on workflow tools, forcing continuous defensive research spending to preserve platform engagement and advertising impression share. |
| Macro discount ratediscount rateThe rate used to convert future cash flows or values into present value.View full glossary entry valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compression | Macroeconomic And Macrofinancial | -11% | -4.0% | Sustained restrictive monetary policy, with policy rates near 4.00% and 10-year Treasury yields hovering near 5.0%, structurally compresses mid-cap technology valuation multiples. Elevated cost of capitalcost of capitalCost of capital is the required return investors demand to fund a business, project, or asset, reflecting risk and financing mix.View full glossary entry penalizes companies experiencing growth moderation, forcing equity valuation to rely strictly on tangible cash yields and share count reduction rather than speculative future enterprise multiples. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Federal ban on digital prescriber marketing | 22% | -42% | Sweeping federal healthcare legislation or administrative rules severely restrict direct pharmaceutical detailing and digital promotional targeting to physicians by early 2028. Because marketing subscriptions generate over 80% of company revenues, capping physician promotional deductibility would paralyze Doximity's commercial engine, slashing operating income by over a third and crushing terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples. Probability is 22% due to aggressive life-sciences lobbying. |
| EHR vendor native workflow lockout | 28% | -36% | Dominant electronic health record monopolists restrict third-party application programming interfaces and bundle native ambient scribes and clinical messaging directly into hospital user interfaces at zero cost by 2027. If clinicians abandon standalone web portals, Doximity's daily physician engagement would drop sharply, cratering advertising impression inventory and destroying net revenue retentionnet revenue retentionRecurring revenue from an existing customer cohort after expansion, contraction, and churn, divided by that cohort's starting recurring revenue.View full glossary entry. Probability is 28% given vendor protectionism. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Enterprise clinical AI subscription breakthrough | 32% | +42% | Doximity successfully converts its Clinical AI Suite into mandatory, enterprise-wide software licenses across more than 500 major health systems by late 2028. Triggered by acute clinician burnout and institutional liability mandates, this adoption doubles health system revenue, decoupling earnings from pharmaceutical advertising cycles and lifting annual revenue growth above 20%. Probability is 32% due to sluggish hospital IT procurement. |
| Federal ban on consumer drug advertising | 26% | +38% | Federal regulatory overhaul or binding FDA rulemaking restricts direct-to-consumer television prescription drug marketing by 2028. This policy shift forces biopharmaceutical companies to reallocate billions in marketing spend into audited, compliant professional clinician channels where Doximity holds dominant market share. Such an influx would accelerate platform ad demand, expanding operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward 45%. Probability is 26% due to pharmaceutical legal resistance. |
Company Financial Analysis
Doximity Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Doximity's financial performance presents a striking contrast between slowing top-line revenue and powerful cash generation. For fiscal 2026, revenue increased 13.05% to $645 million, but growth decelerated to 7.34% in the first quarter of fiscal 2027. GAAP net income contracted sharply, halving to $24.3 million in the latest quarter as spending on artificial intelligence engineering surged over 40%. However, this headline earnings drop conceals underlying cash-flow vitality. Trailing free cash flow reached $299 million, representing an elite 46% conversion margin. Operating performance reflects deliberate, front-loaded software reinvestment rather than structural business decay, providing a highly resilient foundation as commercial marketing commitments stabilize.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | USD 644.9M | USD 196.1M | USD 317.5M |
| 2025 | USD 570.4M | USD 223.2M | USD 266.7M |
| 2024 | USD 475.4M | USD 147.6M | USD 178.3M |
| 2023 | USD 419.1M | USD 112.8M | USD 173.4M |
| 2022 | USD 343.5M | USD 154.8M | USD 120.9M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2026 | 22.7x | TTM | Native | USD / USD |
| 2025 | 51.8x | TTM | Native | USD / USD |
| 2024 | 36.9x | TTM | Native | USD / USD |
| 2023 | 57.5x | Annual | Native | USD / USD |
| 2022 | 71.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
The company commands extraordinary pricing power, maintaining pristine gross profit margins near 89.1% in fiscal 2026. However, GAAP operating margin compressed from 39.9% in fiscal 2025 to 33.3% in fiscal 2026, and gross margins dipped toward 85% in recent quarters due to cloud inference expenses supporting clinical AI queries. This margin compression represents an intentional strategic investment rather than permanent competitive erosion. Core physician distribution carries negligible marginal delivery cost, ensuring that as enterprise software subscriptions scale and search monetization matures, operating leverage will naturally expand margins back toward mid-30% levels.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2026 | USD 214.9M | 33.3% | 30.4% |
| 2025 | USD 227.8M | 39.9% | 39.1% |
| 2024 | USD 163.9M | 34.5% | 31.0% |
| 2023 | USD 125.1M | 29.9% | 26.9% |
| 2022 | USD 113.5M | 33.0% | 45.1% |
Balance sheet and leverage
AI Review
Doximity maintains a fortress balance sheet characterized by zero funded debt, a nominal debt-to-equity ratio of 0.01, and a robust current ratio of 6.09. Liquid assets, comprising approximately $688 million in cash and marketable securities, represent the overwhelming majority of its resource base, ensuring complete operational autonomy. Stockholders' equity declined slightly in fiscal 2026 solely due to $432 million in share repurchases rather than operating losses. With zero refinancing obligations in a high-interest-rate environment, the balance sheet functions as an aggressive capital allocation tool to retire undervalued equity.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2026 | USD 10.2M | USD 748.6M | USD 209M net cash | 6.09x |
| 2025 | USD 12.4M | USD 915.7M | USD 197.2M net cash | 6.97x |
| 2024 | USD 14.5M | USD 762.9M | USD 82.2M net cash | 6.20x |
| 2023 | USD 15.6M | USD 841M | USD 142.4M net cash | 6.99x |
| 2022 | USD 1.1M | USD 798.1M | USD 111.7M net cash | 8.12x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Doximity operates an exceptionally capital-light business, committing just 1.39% of fiscal 2026 revenue, or roughly $9 million, to physical equipment and facilities. Because the company delivers software over existing cloud rails rather than building expensive physical data centers, capital intensity remains structurally minimal. Management directs investment through the income statement, expensing $131 million in research and development to build clinical search and documentation tools. This capital-light architecture liberates immense economic surplus, allowing the company to convert nearly all operating profit into cash that directly funds shareholder-friendly stock buybacks.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2026 | USD 9M | USD 130.7M |
| 2025 | USD 6.5M | USD 93M |
| 2024 | USD 5.8M | USD 82M |
| 2023 | USD 6.2M | USD 80.2M |
| 2022 | USD 5.7M | USD 62.4M |
Quarterly Forecast Scenarios
Doximity Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $24.54 | $26.50 | $27.42 | $750.26 | |
| $23.56 | $27.31 | $28.78 | $736.44 | |
| $23.10 | $28.49 | $31.09 | $743.40 | |
| $22.64 | $29.26 | $32.64 | $755.15 | |
| $22.86 | $30.68 | $34.60 | $776.22 | |
| $22.18 | $31.89 | $37.02 | $787.13 | |
| $21.29 | $33.09 | $38.87 | $802.83 | |
| $21.72 | $34.13 | $40.43 | $812.05 | |
| $21.93 | $35.49 | $42.85 | $839.18 | |
| $21.49 | $36.79 | $45.00 | $850.50 | |
| $21.49 | $38.29 | $46.80 | $872.39 | |
| $21.71 | $39.24 | $48.69 | $885.51 | |
| $22.14 | $40.67 | $51.12 | $909.56 | |
| $21.92 | $41.84 | $53.17 | $916.13 | |
| $22.14 | $43.24 | $55.29 | $936.51 | |
| $22.14 | $44.36 | $58.06 | $947.34 | |
| $22.58 | $45.70 | $60.38 | $969.59 | |
| $22.58 | $46.93 | $62.19 | $979.99 | |
| $22.81 | $48.56 | $64.68 | $999.60 | |
| $23.04 | $49.69 | $66.62 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported consensus demonstrates that the core physician network represents an entrenched medical registry connecting over 80% of domestic prescribers, generating 45% to 49% free cash flow margins and an 8% net buyback yield. However, reports heavily correlated around the assumption that artificial intelligence expenditures are purely discretionary and will effortlessly re-accelerate revenue above 15% are downweighted. Superior independent evidence reveals that generative AI inference costs structurally sit within cost of revenues, trimming gross margins from 89% toward 85%, while stock-based compensation exceeding 20% of sales absorbs a significant portion of share repurchases. The strongest contrarian case correctly identifies that venture-subsidized clinical tools and native hospital electronic health record systems threaten to cap pricing power. Relative weights heavily reward analyses that incorporate these verified cost pressures, dilution realities, and conservative single-digit terminal revenue growth while still recognizing balance sheet resilience.
Universal Investor AI
The Polymath
Opus 5Exceptional factual rigor supported by primary source evidence. Thoroughly unpacks the competitive threat of zero-priced alternatives, regulatory shifts from direct-to-consumer advertising into professional detailing, gross margin compression from inference costs, and dilution leakage from equity compensation.
Universal Investor AI
The Polymath
GPT-6 AstraExemplary analytical discipline grounded in latest SEC filings. Distinguishes unadjusted free cash flow from true owner economic yield after deducting heavy stock-based compensation. Accurately models gradual monetization of clinical search against elevated variable compute and hosting expenses.
Michael Burry AI
The Vulture
Gemini 3.8 FlashSolid analysis linking cash conversion durability and share repurchases to intrinsic valuation floors. It provides sound causal mechanics regarding artificial intelligence search monetization, though it slightly downplays persistent stock-based compensation dilution and competitive pressure from zero-cost clinical search tools.
Universal Investor AI
The Polymath
Gemini 3.8 FlashEffectively balances workflow stickiness and free cash generation against near-term top-line moderation and research overhead. The causal links connecting buyback yields and point-of-care advertising monetization are coherent, though medium-term margin recovery assumptions remain slightly optimistic.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashConstructs a robust macrofinancial framework evaluating sovereign discount rates, sovereign debt cycles, and life-sciences marketing shifts. It accurately contextualizes zero-debt insulation against tight monetary policy, offering disciplined expectations for multi-year cash flow compounding.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashAccurately details enterprise clinical artificial intelligence adoption across major health systems and programmatic advertising migration. It gives fair weight to class-action litigation risks and vendor competition, maintaining a credible path for per-share intrinsic value accretion.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProvides exceptional forensic focus on owner earnings, capital expenditure discipline, and cannibalistic share repurchases. The valuation framework is economically grounded, though it underweights the risk that enterprise hospital software sales face long institutional procurement delays.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashIdentifies compelling regulatory tailwinds, including Sunshine Act compliance and HIPAA compliance, that shield verified digital detailing from traditional sales rep retrenchment. However, it assumes rapid insurer-level prior authorization adoption that exceeds current verified deployment evidence.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashDelivers a sharp, necessary contrarian critique highlighting operating deleverage, media multiple de-rating, and native electronic health record competition. While overly punitive on cash-flow survivability, its warnings regarding defensive engineering spend and multiple compression warrant meaningful portfolio inclusion.
Universal Investor AI
The Polymath
Gemini 3.8 FlashOffers a clear synthesis of asset-light operating leverage, physician workflow integration, and programmatic share retirement. Its valuation baseline provides an appropriate margin of safety, although top-line re-acceleration assumptions outpace near-term pharmaceutical procurement realities.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashPresents strong investigative insight into prescriber engagement metrics and pharmaceutical commercialization dynamics. It appropriately integrates securities class-action litigation risks while demonstrating how normalized cash generation and share repurchases support equity value over multi-year horizons.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashPresents an articulate argument on physician network entrenchment and operating leverage recovery. However, the path relies on aggressive multiple expansion and tripling earnings per share, which minimizes structural pharmaceutical budget headwinds and competitive ambient documentation substitutes.
Elon Musk AI
The Visionary
Gemini 3.8 FlashRaises material concerns regarding compute cost burdens and single-digit revenue saturation. While the terminal multiple stagnation case is well-argued, it underestimates how persistent 45% free cash flow conversion and consistent float retirement protect per-share compounding.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashEmphasizes the durable medical utility moat and defensive fortress balance sheet. The analysis provides sound reasoning regarding gross margin resilience, but its long-term multiple expansion relies on enterprise software conversion rates that remain unproven.
Research Provenance
References & Context
This Doximity consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 49 deduplicated sources retained for this batch.
- 01Documentsec.gov
- 02Doximity, Inc. - Form 10-Q - FY2026sec.gov
- 03Doximity, Inc. - Form 8-K - FY2026sec.gov
- 04Doximity, Inc. - Form 8-K - FY2026sec.gov
- 05Doximity, Inc. - Form 8-K - FY2026sec.gov
- 06Doximity - Doximity Announces Fiscal 2027 First Quarter Financial Resultsinvestors.doximity.com
- 074As Health Earned Media (8-5-26 update) – 4As Health4ashealth.org
- 08Doximity Sinks 24% As AI Push Fails To Ease Growth Fears - Doximity (NYSE:DOCS) - Benzingabenzinga.com
- 09150 Health Systems Are Now on the Doximity Clinical AI Suiteblog.doximity.com
- 10CSRxP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS - CSRxPcsrxp.org
- 11Doximity Scribe: Your AI-Powered Medical Documentation Assistantdoximity.com
- 12pharmaceutical marketing - DTC Perspectivesdtcperspectives.com
- 13OpenEvidence vs Doximity Ask (2026): Full Comparisonevidencemd.ai
- 14Open Evidence AI Review 2026: Features and Alternatives | Fastiofast.io
- 152026 forecast: Pharma ad dollars will continue shifting away from traditional TVfiercepharma.com
And 34 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
11 fieldscash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields
Cash flow
4 fieldscapitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities
annual: 2019-03-31–2026-03-31, 8 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.